Role of anti-domain 1-β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 9, 2016, Pages 1779-1787

  De Craemer, A S ^a   Musial, J ^b   Devreese, K M J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; beta2 glycoprotein I; chemiluminescent assay; domain I; thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY DOMAIN 1; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOANALYSIS; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 84988483807     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13389     Document Type: Article

References (42)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derkesen RHWM, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
2. Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb Res 2012; 130: S37–40.
3. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87: 4120–4.
4. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177–8.
5. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–7.
6. Pelkmans L, Kelchtermans H, de Groot PG, Zuily S, Regnault V, Wahl D, Pengo V, de Laat B. Variability in exposure of epitope G40-R43 of domain I in commercial anti-beta2-glycoprotein I IgG ELISAs. PloS One 2013; 8: e71402.
7. 2-glycoprotein I: the one and only? Lupus 2012; 21: 769–72.
8. Pericleous C, Rahman A. Domain I: the hidden face of antiphospholipid syndrome. Lupus 2014; 23: 1320–3.
9. 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097–103.
10. 2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916–24.
11. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540–5.
12. 2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767–73.
13. 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Ann Rheum Dis 2011; 70: 380–3.
14. 2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res 2011; 128: 583–6.
15. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, Denas G. Padayattil Jose S. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13: 782–7.
16. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–40.
17. van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol 2012; 34: 630–40.
18. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792–5.
19. Fontana P, Poncet A, Lindhoff-Last E, de Moerloose P, Devreese KM. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J Thromb Haemost 2014; 12: 2034–7.
20. Devreese KM, van Hoecke F. Anticardiolipin and anti-beta2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 2011; 128: 598–600.
21. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. CLSI document C28-A3. Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2008.
22. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147–52.
23. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, Horita T, Yasuda S, Koike T. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64: 504–12.
24. Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2013; 72: 142–3.
25. Devreese KM. Standardization of antiphospholipid antibody assays. Where do we stand? Lupus 2012; 21: 718–21.
26. Willis R, Lakos G, Harris EN. Standardization of antiphospholipid antibody testing–historical perspectives and ongoing initiatives. Semin Thromb Hemost 2014; 40: 172–7.
27. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16: 402.
28. Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan E, Facchinetti M, Pengo V. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6: 1693–6.
29. Hollestelle M, van Schangen M, Kariman A, Pequeriaux N. Antibodies against domain I of beta2-glycoprotein I are a better predictor for the antiphospholipid syndrome than antibodies to the total protein [abstract]. Amsterdam: XXIV Congress of the International Society of Thrombosis and Haemostasis, 2013.
30. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimm Rev 2012; 12: 313–7.
31. Zohoury N, Khamashta M, Atsumi T, Musial J, Watanabe T, Papp M, Gonzáles-Rodríguez C, Albesa R, Norman GL, Meroni PL, Mahler M. Autoantibodies targeting domain 1 of beta 2 glycoprotein I as a promising marker in the diagnosis and risk stratification of the antiphospholipid syndrome [abstract]. Arthritis Rheum 2013; 65: S4.
32. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Maronqiu F, Bison E, Denas G, Banzato A. Padayattil Jose S, Iliceto S. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–42.
33. 2 glycoprotein I antibodies in systemic autoimmune diseases [abstract]. Arthritis Rheum 2013; 65: S4.
34. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123: 482–7.
35. Forastiero R. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 2014; 23: 1252–4.
36. 2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598–602.
37. Zoghlami-Rintelen C, Vormittag R, Sailer T, Lehr S, Quehenberger P, Rumpold H, Male C, Pabinger I. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160–5.
38. Devreese K, Kelchtermans H, de Laat B. Differences in sensitivity of two automated panels for anticardiolipin and anti-β2 glycoprotein antibodies in the laboratory diagnosis of antiphospholipid syndrome due to the exposure of the domain I epitope of β2glycoprotein I on the solid phase [abstract]. J Thromb Haemost 2014; 12: LA06.
39. Meneghel L, Ruffatti A, Gavasso S, Tonello M, Mattia E, Spiezia L, Tormene D, Hoxha A, Fedrigo M, Simioni P. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta 2015; 446: 201–5.
40. 2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014; 431: 174–8.
41. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni PL, Ortel TL, Petri M, Rahman A, Roubey R, Sciasia S, Snyder M, Tebo AE, Tincani A, Willis R. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimm Rev 2014; 13: 917–30.
42. Pengo V, Ruffatti A, Del Ross T, Tonello M, Cuffaro S, Hoxha A, Banzato A, Bison E, Denas G, Bracco A, Padayattil Jose S. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013; 11: 1527–31.